Re: Trading
in response to
by
...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Message: Re: Trading
Canadian Securities Administration:
| Issued Date | Issuing Jurisdiction(s) | Status | Expiry Date | Exception | Type | ||||||
|
Active Cease Trade Orders |
|||||||||||
| 2022/09/07 | AB-ON | Issued | None | No | Ban Securities Trading OF |
Koo
New Message
Please
login
to post a reply